Clinical Trials Logo

ß-thalassemia clinical trials

View clinical trials related to ß-thalassemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06440603 Not yet recruiting - ß-thalassemia Clinical Trials

EKLF Gene Expression in β-thalassemia

Start date: July 1, 2024
Phase:
Study type: Observational

1. Studying the effect of expression pattern of EKLF gene in β-thalassemic patients. 2. Detecting the correlation between the gene expression of EKLF and the clinical phenotype of β-thalassemic patients.

NCT ID: NCT06377865 Not yet recruiting - B Thalassemia Clinical Trials

Thyroid Function , HbA1c in Relation to Ferritin Level in Adullt Patient e B Thalassemia

Start date: May 1, 2024
Phase:
Study type: Observational

to evaluate thyroid function ,HbA1C,&lipid profile in thalassemic patient to correlate thyroid function , Hba1c , lipid profile e ferritin level in thalassemic patient

NCT ID: NCT05105659 Not yet recruiting - B Thalassemia Clinical Trials

Assessment of Cognitive Functions, Psychological Symptoms, and Quality of Life Among B Thalassemia Patients and Their Clinical Correlates.

Start date: December 20, 2021
Phase:
Study type: Observational

Multiple studies showed the negative impact thalassemia disease and its therapy have on the cognition of these patients. This study aims to assess and compare the cognition, psychological impact and quality of life among patients with B thalassemia major, requiring regular blood transfusion, patients with B thalassemia intermedia, who don't, and healthy controls. Thus, estimating the role of blood transfusion and hemosiderosis in cognitive impairment, psychological symptoms, and low quality of life in these patients.

NCT ID: NCT03358498 Not yet recruiting - ß-thalassemia Clinical Trials

Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox

Start date: December 1, 2017
Phase: N/A
Study type: Observational

Regular blood transfusions are essential for the management of haematological conditions such as β-thalassemia major. As a result, however, patients with these conditions are susceptible to the development of transfusion-dependent iron overload (hemosiderosis or secondary iron overload